Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025

Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025

Press Release Comments Off on Biosimilars Market Is Expected To Reach US$ 25.83 Bn By 2025

Biosimilars Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025

Biosimilars Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017 – 2025, the Biosimilars market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83 Bn by 2025, expanding at a CAGR of 23.1% from 2017 to 2025.

View Full Report with TOC @ http://www.acutemarketreports.com/report/biosimilars-market

Market Insights

Biosimilars are the products approved in a country which has an abbreviated approval process for biologic products that refer to an originator biologic in the regulatory submission. Biosimilars possess similar clinical properties like safety, potency and purity as compared to the original biological product. The currently available biosimilars treatment segment are by product and application. The product segment comprises of recombinant non-glycosylated proteins (Insulin, Filgastrim, Somatropin) recombinant glycosylated proteins (Monoclonal antibodies, Erythropoietin) and recombinant peptides (Glucagon, Calcitonin).The application segment comprises of oncology, chronic and autoimmune disease, blood disorders, growth hormone disease and infectious disease. The key factors assisting the growth of biosimilars are the increasing prevalence of chronic disease, rising aging population, patient inclination towards reduced healthcare expenditure and government initiatives to promote biosimilars for e.g. Europe Medicines Agency (EMA) has finalized the guidelines on biosimilars with its elements described in ICH (Q5E). On the other hand, high complexities involved in the manufacturing of biosimilars and the rigorous regulatory framework governing their approval in countries around the world are hindering the market growth of biosimilars.

Download Free Sample Report @ http://www.acutemarketreports.com/request-free-sample/44143

Pipeline Analysis

Pipeline of biosimilar market comprises of (recombinant non-glycosylated proteins, recombinant glycosylated proteins and recombinant peptides). Samsung Bioepis (SB4, SB2, SB5, SB9), Sandoz (GP2015, LA-EP2006, HX575), Amgen (ABP 501, ABP 980, ABP 215), Momenta (M923, M834) etc. We have estimated sales of very specific molecules based on the above mentioned type, disease prevalence, sponsor, depicted peak sales by leading market experts and other factors.

Key Market Movements:

  • Rising prevalence of cancer and chronic disease in developed and developing countries
    • Increasing geriatric population and high public awareness in developed countries is expected to boost the biosimilars market
    • Expiry of patents of biologicals coupled with government initiatives to promote biosimilars
    • Increased patient inclination towards cost effective healthcare solutions

View Full Report with TOC @ http://www.acutemarketreports.com/report/biosimilars-market

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.

Contact info:

Name: Chris Paul

Designation: Global Sales Manager

Email:  sales@acutemarketreports.com

Ph:  +1-855-455-8662

Web: www.acutemarketreports.com

Author

Back to Top